Pulmonary Care: Advancing Respiratory Health Through Science, Scale, and Strategic Leadership
At our globally preeminent pharmaceutical corporation, the Pulmonary Division stands as a strategic growth engine and a cornerstone of our commitment to public health. Respiratory diseases represent one of the most pressing and complex healthcare challenges of our time—particularly in India, where environmental exposure, infectious disease burden, and lifestyle factors converge at unprecedented scale. Our mission is clear: to transform pulmonary care for India’s 1.4 billion people while contributing decisively to global respiratory health, which affects more than 2 billion individuals worldwide.

We address the full spectrum of respiratory disease—from chronic obstructive pulmonary disease (COPD), asthma, and allergic disorders to community-acquired respiratory infections and tuberculosis (TB)—through a comprehensive, science-led portfolio designed to deliver measurable clinical outcomes, operational scalability, and long-term system resilience.

Our strategy integrates advanced pharmacotherapy, biologics, diagnostics, and digital health to ensure continuity of care across prevention, early diagnosis, treatment, and long-term disease management. In doing so, we convert India’s respiratory disease burden into a platform for globally relevant innovation—where frugal, high-quality solutions developed for local needs set benchmarks for international care delivery.

Epidemiology, Disease Drivers, and Risk Landscape

India faces a respiratory disease burden of exceptional magnitude and complexity. COPD affects an estimated 55–65 million people, driven by household biomass fuel exposure, ambient air pollution, tobacco consumption, and occupational hazards. Seasonal and community-acquired respiratory infections result in tens of millions of episodes annually, exacerbated by climate variability, antimicrobial resistance, and uneven access to diagnostics.

Allergic rhinitis and asthma are rising sharply, particularly in urban and peri-urban populations, fueled by air pollution, aeroallergens, and changing lifestyles. Tuberculosis remains a critical national priority, with India accounting for nearly one-quarter of the global TB burden, compounded by undernutrition, diabetes co-morbidity, HIV co-infection, and emerging drug resistance.

Globally, chronic respiratory diseases and TB account for over 4.5 million deaths each year, with low- and middle-income countries bearing the greatest impact. Rapid urbanization, climate change, e-cigarette use, and antimicrobial resistance continue to intensify the challenge, reinforcing the need for integrated, globally coordinated pulmonary solutions.

A Comprehensive, Precision-Led Pulmonary Portfolio

Our Pulmonary Division delivers a differentiated and future-ready portfolio spanning chronic, acute, allergic, and infectious respiratory conditions. Our offerings include:

• Advanced inhaled therapies, including triple fixed-dose combinations (ICS/LABA/LAMA) designed to improve adherence and lung function across asthma–COPD phenotypes
• Targeted biologics for severe and eosinophilic respiratory disease, enabling personalized control of inflammation and exacerbations
• Optimized anti-infective regimens for community-acquired and drug-resistant pneumonias
• Next-generation TB therapies, aligned with shortened treatment durations and improved tolerability
• Digital and device-enabled solutions, including smart inhalers and AI-supported monitoring for real-world disease management
• Each therapy is developed with a strong focus on clinical evidence, patient usability, and relevance to Indian epidemiology, while meeting international quality and regulatory standards.
• Our work is closely aligned with India’s National TB Elimination Programme, Ayushman Bharat – PM-JAY, and national asthma and COPD guidelines, while remaining harmonized with global frameworks.

Vision and Strategic Imperatives

Our vision is unequivocal: to enable every individual to breathe freely—without preventable limitation, delay, or disparity.

To realize this ambition, our pulmonary strategy is anchored in four strategic imperatives:

• Portfolio Expansion and Innovation
• Accelerating development of next-generation inhaled therapies, biologics, and host-directed treatments for complex respiratory conditions.
• India-Centric R&D with Global Relevance
• Investing in large-scale, India-anchored clinical research that reflects genetic, environmental, and disease diversity while meeting global regulatory standards.
• Digital Enablement and Access at Scale
• Leveraging tele-pulmonology, AI-enabled diagnostics, and adherence technologies to extend specialist care beyond urban centers.

Integrated Public Health Impact

Supporting national disease control programs, antimicrobial stewardship, pollution mitigation, and TB elimination efforts through public–private collaboration.

Demonstrated Impact and Business Performance

Our Pulmonary Division has delivered consistent clinical and commercial outcomes, supporting tens of millions of patients annually. Our therapies have contributed to meaningful reductions in exacerbations, hospitalizations, and treatment discontinuation across asthma, COPD, and TB programs.

Digital adherence platforms and remote monitoring tools have significantly improved treatment success rates and narrowed urban–rural access gaps. These initiatives have strengthened our position as a trusted partner to healthcare systems while driving sustainable growth across domestic and international markets.

Addressing Persistent Challenges

Despite progress, challenges remain. High out-of-pocket expenditure, limited access to diagnostics in rural regions, environmental pollution, stigma surrounding TB, and the emergence of drug resistance continue to threaten respiratory health outcomes.

We address these barriers through affordability-driven innovation, resilient supply chains, clinician education, digital traceability, and policy engagement, ensuring long-term sustainability alongside scale.

Enduring Commitment and Future Outlook

Guided by our core values of scientific excellence, ethical integrity, patient-centricity, and collaborative partnership, we continue to invest decisively in pulmonary research, manufacturing, and access. Through alliances with government agencies, global health organizations, technology partners, and healthcare providers, we are building resilient respiratory care ecosystems capable of meeting today’s needs and tomorrow’s risks.

Our ambition is bold yet grounded: to improve respiratory health outcomes for over 1.5 billion people by 2035, significantly reduce respiratory disease-related disability and mortality, and establish India as a global hub for pulmonary innovation and affordable excellence.

Because the ability to breathe freely is fundamental—and advancing respiratory health is essential to a healthier, more productive world.